Vaccine Info

JNJ-1802 Dengue Antiviral

Authored by
Last reviewed
March 20, 2023
Fact checked by
Robert Carlson, MD

JNJ-1802 Dengue Antiviral 2023

Janssen Pharmaceutical Companies JNJ-1802 first-in-class dengue antiviral uses a novel mechanism of action to prevent the interaction between two viral proteins (NS3 and NS4B), thereby stopping the ability of the virus to replicate. JNJ-1802 was shown to be safe and well tolerated in a Phase 1 first-in-human clinical study and is progressing into Phase 2 clinical studies for the prevention and treatment of dengue.

Recent data indicate JNJ-1802 is effective against all four dengue serotypes in mouse models and provides strong protection against two tested serotypes (DENV-1 and -2) in non-human primates. These findings build on research published in the journal Nature in 2021 that first identified the novel mechanism of action from the same chemical series as JNJ-1802.

Janssen Pharmaceutical Companies focuses on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology,  Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

New Jersey-based Johnson & Johnson’s work against dengue is one part of a larger, more than 15-year legacy working to address the burden of Neglected Tropical Diseases, a group of about 20 communicable diseases that affect more than 1.7 billion people in 149 countries around the world. Additionally, the Company launched the Satellite Center for Global Health Discovery at Duke-NUS Medical School in Singapore in June 2022, which is focused on accelerating early-stage discovery research to address the growing challenge of flaviviruses, including dengue. 

JNJ-1802 Indication

JNJ-1802 is indicated to protect people against four dengue serotypes. Current research supports the further clinical development of JNJ-1802 for both the prevention and treatment of dengue. Dengue reinfection is possible due to the presence of four dengue serotypes.

JNJ-1802 News 2023

March 15, 2023 - Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Preclinical Data Published in Nature.

October 6, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced the publication of preclinical data in the journal Nature showing that an early-stage compound with a novel mechanism of action could potentially treat all serotypes of dengue fever and provide a period of protection against acquiring the dengue virus.

JNJ-1802 Clinical Trials

Phase 2 clinical trial - Last Update Posted: February 16, 2023.

Phase 2 Identifier: NCT04906980 - Last Update Posted: March 15, 2023.

The Phase 1 double-blind, randomized, placebo-controlled study was conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of the novel dengue antiviral compound, which is being developed to prevent dengue. Results from the study show that Janssen’s breakthrough compound administered orally in single or multiple doses, was safe and well-tolerated, with no serious adverse events reported. The preclinical results also demonstrated promising safety data and excellent efficacy at preventing dengue virus infection in mouse and non-human primate models by blocking the interaction between two viral proteins (NS3 and NS4B) that are needed in the replication process of the dengue virus.

Clinical Trials

No clinical trials found